E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10047715 |
E.1.2 | Term | Von Willebrand's disease |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10047715 |
E.1.2 | Term | Von Willebrand's disease |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. To investigate the initial and repeat pharmacokinetic profile of Biostate in subjects with VWD. 2. To assess the haemostatic efficacy of Biostate in subjects with VWD who require a Von Willebrand Factor product to control a non-surgical bleeding (NSB) event. 3. To assess the effectiveness of a prophylaxis regimen as compared to on-demand therapy with Biostate in preventing NSB events. |
|
E.2.2 | Secondary objectives of the trial |
1. To assess the safety of Biostate used both as on-demand therapy to treat NSB events and as prophylactic therapy. 2. To assess the haemostatic efficacy of Biostate for subjects who undergo surgical procedures during the study period. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male and female subjects who are at least 12 years of age. 2. Diagnosed with VWD where VWF:RCo is <15% at screening (after a minimum of 5 days since last VWF treatment) or the subject has a history of VWF:RCo <10% documented in their medical notes at enrolment. 3. Where DDAVP treatment is ineffective or contraindicated. 4. Require a VWF product for prophylactic therapy or to control a NSB event. 5. Have evidence of vaccination against hepatitis A and B (or presence of antibodies against hepatitis A and B due to either a previous infection or immunisation) within 10 years prior to their first dose of Biostate documented in their medical notes. 6. The subject and/or their legally acceptable representative understands the nature of the study, gives written informed consent to participate in the study and is willing and able to comply with the protocol. |
|
E.4 | Principal exclusion criteria |
For participants of the PK study: 1. Are actively bleeding immediately prior to initial PK period. 2. Have received DDAVP or a VWF product in the 5 days prior to their first dose of study product. 3. Have Type 2B, 2N or 2M VWD. For all subjects: 4. Requiring a VWF product for a planned surgical procedure at enrolment (treatment with Biostate for surgical procedures subsequent to enrolment in the study is allowed but a planned surgery should not be the reason for inclusion into the study). 5. Have received aspirin or other NSAIDs within 7 days prior to their first dose of study product. 6. Have a known history of, or are suspected to have VWF or FVIII inhibitors. 7. Suffering an acute or chronic medical condition, other than VWD, which may, in the opinion of the Investigator, affect the conduct of the study. 8. Have a known or suspected hypersensitivity or previous evidence of severe side effects to Biostate, VWF/FVIII concentrates or human albumin. 9. Subjects with impaired liver function at screening i.e. bilirubin >1.5 x upper limit of normal (ULN) and/or, AST/ALT >2.5 x ULN (referring to the limits of the laboratory that performs the determination). 10. Subjects having evidence or a history (within the previous 12 months) of abuse of any drug substance, licit or illicit. 11. Have participated in a clinical study or used an investigational compound (e.g. a new chemical entity not registered for clinical use) in the three months preceding the first day of study drug administration, or who are planning to enter such a study during the study period. 12. Female subjects who are pregnant, breast-feeding or who have a positive pregnancy test at screening. The Investigator must confirm that a reliable form of contraception will be used for the duration of the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Pharmacokinetic (PK) parameters for each measure of VWF and Factor VIII (FVIII) activity will be derived from plasma concentration values collected following: • an initial single dose of Biostate on Day 1. • a repeat single dose in Type 3 subjects after a minimum of 6 months of study participation (with at least 2 doses of Biostate to have been administered since the Day 1 dose). • Assessment of haemostatic efficacy of Biostate in the treatment of a NSB event according to a 4 point ordinal scale. • Number of NSB events per month during the prophylaxis period as compared to the on-demand period. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 4 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 15 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 15 |